1963. Package # 440 (Determining the risk of cancer development in a man)
Turnaround time (days): 1
3410 ₴
Description
The package ‘Determining the risk of developing cancer in men’ is a complex of oncomarkers that allow assessing the risks of the most common oncological diseases in men: the neuroendocrine system (neuron-specific enolase (NSE)), pancreatic and gallbladder tumors (CA 19-9), stomach (CA 72-4), tumors of the bladder (tumor marker Cyfra CA 21-1 (cytokeratin 19 fragment)), prostate gland (prostate-specific antigen (PSA) total, free and their ratio as a percentage), benign and malignant neoplasms of the intestinal tract (cancer-embryonic antigen (CEA, SEA)) and tumor process in the liver (α-fetoprotein (AFP)).
These studies are recommended for men for a comprehensive risk assessment of a wide range of cancers, especially if any of the relatives have or had cancer. In case of a change in the oncomarker, an additional examination is necessary, since an increase in indicators can be observed not only in the case of cancer, but also in inflammatory and benign processes.
It is important to take this complex before the examination of the prostate gland (finger or ultrasound) or a week after.
When and who needs the test?
It is recommended to take this package to assess the risks of developing the most common forms of cancer in men.
Biological material
- Venous blood
Preparation for blood testing for PSA
In order to exclude factors that may affect the test results, we recommend to follow the preparation rules:
- fn important condition for laboratory tests is to take blood on an empty stomach. 6-12 hours before the test, you should avoid eating, drinking alcohol, smoking, and limit physical activity. Drinking...